Diffuse large B-cell lymphoma · 13 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibritumomab tiuxetan protocol Variant #18 | — | R 27 524 | 8d | ~36.5 mo | — | ~139 | ~R 3 825 804 PFS proxy · indirect | 1 |
R-IFE Variant #01 | — | R 15 682 | 14d | — | — | — | — | — |
CBV-Mx Variant #01 Partial | — | R 15 375 | — | — | — | — | — | — |
Z-BEAM Variant #01 Partial | — | R 12 158 | — | — | — | — | — | — |
Cytarabine and Methotrexate (CYM) Variant #03 | — | R 5 979 | 21d | — | — | — | — | — |
Cyclophosphamide and TBI Variant #01 | — | R 1 176 | — | — | ~90.0 mo | — | — | 1 |
Cytarabine monotherapy Variant #01 | — | R 366 | 30d | — | — | — | — | — |
CBV N/A - secondary systemic drug Partial | — | R 43 | — | — | — | — | — | 2 |
Radiation therapy N/A - radiation Partial | — | — | 49d | — | — | — | — | 1 |
Placebo Partial | — | — | — | 58.9 mo | — | — | — | 1 |
TBI Variant #01 Partial | — | — | — | — | — | — | — | 2 |
Observation Partial | — | — | — | — | ~37.1 mo | — | — | 3 |
Methotrexate monotherapy Partial | — | — | — | ~2.6 mo | ~6.7 mo | — | — | 10 |
13 of 13 regimens shown